Organogenesis Holdings (ORGO) Cash & Equivalents (2015 - 2026)

Organogenesis Holdings' Cash & Equivalents history runs 11 years deep, the most recent figure standing at $91.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 16.9% year-over-year to $91.4 million; the TTM figure through Mar 2026 stood at $91.4 million (down 16.9% YoY), while the FY2025 annual figure was $93.7 million, down 30.9% from the prior year.
• Cash & Equivalents was $91.4 million for Q1 2026 at Organogenesis Holdings, down from $93.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $135.6 million in Q4 2024 to a low of $63.7 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $97.1 million across 5 years, with a median of $94.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 30.56% in 2024, then sank 32.43% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $102.5 million in 2022, then climbed by 1.33% to $103.8 million in 2023, then soared by 30.56% to $135.6 million in 2024, then sank by 30.9% to $93.7 million in 2025, then slipped by 2.46% to $91.4 million in 2026.
• The last three Cash & Equivalents figures came in at $91.4 million (Q1 2026), $93.7 million (Q4 2025), and $63.7 million (Q3 2025), per Business Quant data.